Compares two ways to treat high blood pressure in adults
Compares remote prescribing with usual care and extra blood pressure checks.
Plain-language title generated from the registry record
Registry title: Optimised Treatment for Hypertension Trial
Key facts
- Where
- Sydney, AustraliaSee the site
Where in Australia
- The George Institute for Global HealthSydney, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The George Institute
- Trial code
- NCT06935760
- Record updated
- 21 August 2025
- Original description
This randomized trial compares two prescribing strategies to treat high blood pressure. One approach involves remote treatment informed by randomized trial evidence without regular monitoring of blood pressure ("fire and forget"), whilst the other involves usual care treatment with access to frequent blood pressure monitoring. The study will enrol participants with uncontrolled high blood pressure and randomize participants 1:1 to a "fire and forget" treatment group or a "more blood pressure monitoring" group for a total of 12 weeks. "Fire and forget" involves choosing the most appropriate treatment based on the highest quality evidence (randomized trial data), after which participants will stop measuring blood pressures until the end of study. The "more blood pressure monitoring" group will involve treatment as usual but with the access to frequent and high quality blood pressure monitoring.Read full original descriptionShow less
Optimised Treatment for Hypertension Trial - A Feasibility and Pilot Trial of Fire and Forget Versus Usual Care With Intensive Blood Pressure Monitoring for Optimal Hypertension Care
This randomized trial compares two prescribing strategies to treat high blood pressure. One approach involves remote treatment informed by randomized trial evidence without regular monitoring of blood pressure ("fire and forget"), whilst the other involves usual care treatment with access to frequent blood pressure monitoring. The study will enrol participants with uncontrolled high blood pressure and randomize participants 1:1 to a "fire and forget" treatment group or a "more blood pressure monitoring" group for a total of 12 weeks. "Fire and forget" involves choosing the most appropriate treatment based on the highest quality evidence (randomized trial data), after which participants will stop measuring blood pressures until the end of study. The "more blood pressure monitoring" group will involve treatment as usual but with the access to frequent and high quality blood pressure monitoring.
The goal of this research is to:
1. determine which prescribing approach is more effective at lowering blood pressure after 12 weeks (end of study) 2. assess the safety, feasibility and acceptability of the two treatment approaches.
Inclusion: Written Informed consent; Adult aged ≥18 years; English proficiency; High BP defined as home SBP ≥135 or DBP ≥85 mmHg, either untreated or receiving one or two BP lowering drugs; Among untreated individuals, indicated for pharmacological treatment of high BP according to 2023 Australian Heart Foundation Cardiovascular Risk Management Guidelines; Willing to receive BP lowering drug treatment remotely if treatment is indicated; Willing to check BP with home monitoring for 12 weeks; Willing to participate in telehealth visit at baseline and 12 weeks; Willing to undergo blood tests.
Exclusion: Currently receiving three or more BP lowering drugs; Currently receiving an antihypertensive that is not one of the five major antihypertensive drug classes; Home SBP ≥150 mmHg for participants on one BP lowering drug; Home SBP ≥145 mmHg for participants on two BP lowering drugs; Any abnormalities on baseline electrolytes that would prevent initiation of BP lowering therapy; Participants with any other medical condition or taking any other concomitant medication which in the opinion of the investigator would make the participant unsuitable for the trial; Baseline eGFR <45 ml/min/m2; Of childbearing age and not using contraception; Home SBP ≥155 mmHg for untreated participants; Planned international travel for next 12 weeks.